106 related articles for article (PubMed ID: 26254343)
1. Novel Molecular Targets for the Therapy of Urothelial Cancer.
Jana BR; Zhou Y
Anticancer Res; 2015 Sep; 35(9):4557-67. PubMed ID: 26254343
[TBL] [Abstract][Full Text] [Related]
2. Novel molecular targets for the therapy of urothelial carcinoma.
Jana BR; Galsky MD; Hahn NM; Milowsky MI; Sonpavde G
Expert Opin Ther Targets; 2012 May; 16(5):499-513. PubMed ID: 22510032
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for urothelial carcinoma.
Gartrell BA; Sonpavde G
Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
6. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
Galsky MD; Seng S; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Clin Genitourin Cancer; 2011 Sep; 9(1):27-30. PubMed ID: 21700509
[TBL] [Abstract][Full Text] [Related]
8. Systemic chemotherapy for urothelial cancer.
Sonpavde G; Hutson TE; Berry WR
Clin Genitourin Cancer; 2006 Jun; 5(1):34-42. PubMed ID: 16859577
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular targets for urothelial carcinoma.
Faltas BM; Karir BS; Tagawa ST; Rosenberg JE
Expert Opin Ther Targets; 2015 Apr; 19(4):515-25. PubMed ID: 25633079
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
Buti S; Ciccarese C; Zanoni D; Santoni M; Modena A; Maines F; Gilli A; Bria E; Brunelli M; Rimanti A; Cascinu S; Ardizzoni A; Tortora G; Massari F
Future Oncol; 2015; 11(1):107-19. PubMed ID: 25572786
[TBL] [Abstract][Full Text] [Related]
11. Targeted agents in second-line bladder cancer therapy.
Gerullis H; Otto T; Ecke TH
Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
[TBL] [Abstract][Full Text] [Related]
12. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Teo MY; Bambury RM; Zabor EC; Jordan E; Al-Ahmadie H; Boyd ME; Bouvier N; Mullane SA; Cha EK; Roper N; Ostrovnaya I; Hyman DM; Bochner BH; Arcila ME; Solit DB; Berger MF; Bajorin DF; Bellmunt J; Iyer G; Rosenberg JE
Clin Cancer Res; 2017 Jul; 23(14):3610-3618. PubMed ID: 28137924
[No Abstract] [Full Text] [Related]
13. A critical review on ramucirumab in the treatment of advanced urothelial cancer.
Vlachostergios PJ; Lee A; Thomas C; Walsh R; Tagawa ST
Future Oncol; 2018 May; 14(11):1049-1061. PubMed ID: 29231057
[TBL] [Abstract][Full Text] [Related]
14. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
Sonpavde G; Sternberg CN; Rosenberg JE; Hahn NM; Galsky MD; Vogelzang NJ
Lancet Oncol; 2010 Sep; 11(9):861-70. PubMed ID: 20537950
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
Balar AV; Milowsky MI
Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
[TBL] [Abstract][Full Text] [Related]
16. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.
Aparicio AM; Elkhouiery AB; Quinn DI
Urol Clin North Am; 2005 May; 32(2):217-30, vii. PubMed ID: 15862619
[TBL] [Abstract][Full Text] [Related]
17. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy for advanced bladder cancer: update and controversies.
Garcia JA; Dreicer R
J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in advanced urothelial carcinoma.
Verdoorn BP; Kessler ER; Flaig TW
Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Vaughn DJ
Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
